Thomas Eggerman, M.D., Ph.D.
Responsibilities & Activities
I am the program officer for Cystic Fibrosis grants and Centers programs. The focus is on the non-pulmonary aspects of Cystic Fibrosis.
I am also the program officer for the Rare Metabolic Disease and Advanced Artificial Pancreas Clinical Trials programs.
Additionally, I am the program director for the Human Islet Research Network (HIRN) Enhancement Center and the Integrated Islet Distribution Program (IIDP). I am the Scientific Officer for the Collaborative Islet Transplantation Registry, the Covid Diabetes Assessment Consortium and the Lysosomal Disease Network.
Research Programs
Cystic Fibrosis
Etiology, molecular pathogenesis, pathophysiology, diagnosis, and treatment of cystic fibrosis and its complications.
Cystic Fibrosis Research & Translation Centers
CFRTCs provide support for basic, preclinical, and clinical research efforts to advance scientific knowledge and new therapies for CF.
Endocrine Pancreas
Biology, development, and function of the endocrine pancreas and clinical studies on islet transplantation for type 1 diabetes treatment.
Genetic Metabolic Disease
Basic and clinical studies on the pathophysiology and treatment of inborn errors of metabolism and rare genetic metabolic diseases.
Committees & Working Groups
- Type 1 Diabetes Working Group, Member
- HIRN Working Group, Member
- DEM Clinical Oversight Committee, Member
- Rare Disease Clinical Trials Network, Member
Select Experience
Clinical Staff, NHLBI, NIH, 1993–Present
Senior Research Investigator and Medical Officer, Cell and Gene Therapy, U.S. Food and Drug Administration, 1993–2001
Endocrine Fellowship, Molecular Disease Branch, NHLBI, NIH, 1989–1993
Medical Staff Fellow, Molecular Disease Branch, NHLBI, NIH, 1987–1989